Literature DB >> 21666219

Impact of measles eradication activities on routine immunization services and health systems in Bangladesh.

Tracey Pérez Koehlmoos1, Jasim Uddin, Haribondu Sarma.   

Abstract

BACKGROUND: Seroprevalence studies suggest that vaccination coverage of 90%-95% is needed to eliminate measles. In Bangladesh, routine measles vaccination coverage rates have recently reached 80%-85%. The Government of Bangladesh implemented catch-up vaccination through supplementary immunization activities (SIAs). The aim of the present study was to understand the impact of SIAs on immunization services and the health system.
METHODS: The study was conducted at 4 sites, all of which had relatively low routine vaccination coverage rates. A document review was performed, followed by interviews of key personnel selected by purposive and snowball sampling. A staff profiling survey was also undertaken.
RESULTS: Despite overall high levels of immunization, the expanded program on immunization for measles has not reached the coverage levels targeted by the Government of Bangladesh. The first SIAs vaccinated 35 million children, and the second targeted an additional 20 million. According to data and respondents, implementation of the SIAs was successful with sufficient funds being available, although timely disbursement of funds was inadequate in some areas. Staff were well motivated, and additional training helped boost a positive approach to vaccination.
CONCLUSIONS: The SIAs had a positive impact on health and immunization systems and have created a framework on which other health care interventions for bacterial and viral diseases could be based.
© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666219     DOI: 10.1093/infdis/jir086

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Impact of measles supplementary immunization activities on reaching children missed by routine programs.

Authors:  Allison Portnoy; Mark Jit; Stéphane Helleringer; Stéphane Verguet
Journal:  Vaccine       Date:  2017-11-23       Impact factor: 3.641

2.  Arsenic exposure and serum antibody concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth cohort in Bangladesh.

Authors:  Barrett M Welch; Adam Branscum; Sharia M Ahmed; Perry Hystad; Ellen Smit; Sakila Afroz; Meghan Megowan; Mostofa Golam; Md Omar Sharif Ibne Hasan; Mohammad L Rahman; Quazi Quamruzzaman; David C Christiani; Molly L Kile
Journal:  Environ Int       Date:  2019-04-30       Impact factor: 9.621

3.  The effects of maternal immunity and age structure on population immunity to measles.

Authors:  A McKee; M J Ferrari; K Shea
Journal:  Theor Ecol       Date:  2015-05       Impact factor: 1.432

4.  Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.

Authors:  Aaron S Wallace; Rajendra Bohara; Steven Stewart; Giri Subedi; Abhijeet Anand; Eleanor Burnett; Jagat Giri; Jagat Shrestha; Suraj Gurau; Sameer Dixit; Rajesh Rajbhandari; W William Schluter
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

Review 5.  Partnerships in the introduction of new routine vaccines in Bangladesh: evidence from a prospective process evaluation.

Authors:  Sharmin Khan Luies; Tahmina Sultana; Ashwin Budden; Mohammad Asaduzzaman; Md Billal Hossain; Matthew Kelly; Darren Gray; Md Jasim Uddin; Haribondhu Sarma
Journal:  BMJ Open       Date:  2022-09-26       Impact factor: 3.006

6.  Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.

Authors:  Md Jasim Uddin; Gourab Adhikary; Md Wazed Ali; Shahabuddin Ahmed; Md Shamsuzzaman; Chris Odell; Lauren Hashiguchi; Stephen S Lim; Nurul Alam
Journal:  BMC Infect Dis       Date:  2016-08-12       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.